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Targeting SOX10-deﬁcient cells to reduce the
dormant-invasive phenotype state in melanoma
Claudia Capparelli1,2 ✉, Timothy J. Purwin 1, McKenna Glasheen 1, Signe Caksa 1, Manoela Tiago1,
Nicole Wilski 1, Danielle Pomante1, Sheera Rosenbaum1, Mai Q. Nguyen1, Weijia Cai 1,
Janusz Franco-Barraza3, Richard Zheng4, Gaurav Kumar1,2, Inna Chervoneva 5,6, Ayako Shimada 5,6,
Vito W. Rebecca7,8, Adam E. Snook 2,6, Kim Hookim9, Xiaowei Xu10, Edna Cukierman 3,
Meenhard Herlyn 7 & Andrew E. Aplin 1,2 ✉

Cellular plasticity contributes to intra-tumoral heterogeneity and phenotype switching, which
enable adaptation to metastatic microenvironments and resistance to therapies. Mechanisms
underlying tumor cell plasticity remain poorly understood. SOX10, a neural crest lineage
transcription factor, is heterogeneously expressed in melanomas. Loss of SOX10 reduces
proliferation, leads to invasive properties, including the expression of mesenchymal genes
and extracellular matrix, and promotes tolerance to BRAF and/or MEK inhibitors. We identify
the class of cellular inhibitor of apoptosis protein-1/2 (cIAP1/2) inhibitors as inducing cell
death selectively in SOX10-deﬁcient cells. Targeted therapy selects for SOX10 knockout cells
underscoring their drug tolerant properties. Combining cIAP1/2 inhibitor with BRAF/MEK
inhibitors delays the onset of acquired resistance in melanomas in vivo. These data suggest
that SOX10 mediates phenotypic switching in cutaneous melanoma to produce a targeted
inhibitor tolerant state that is likely a prelude to the acquisition of resistance. Furthermore, we
provide a therapeutic strategy to selectively eliminate SOX10-deﬁcient cells.
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ntratumoral heterogeneity and cellular plasticity between
states with differing proliferative, invasive, and drug phenotypes allow tumors to adapt to foreign microenvironments
during the metastatic process1. While it is known that cellular
plasticity involves reprogramming of transcriptional proﬁles, the
mechanisms that mediate phenotypic switching are poorly
characterized. Heterogeneity and plasticity are evident in cutaneous melanoma and are associated with non-responsiveness and
acquired resistance to pharmacological inhibitors of the BRAFMEK signaling pathway and to immune checkpoint antibodies
such as anti-PD1 and anti-CTLA42–4.
Melanomas arise from the transformation of neural crest (NC)derived cells. These highly aggressive tumors frequently show
remarkable growth inhibition when treated with targeted BRAF
inhibitors (BRAFi) and/or MEK inhibitors (MEKi). However,
these effects are transient, and eventually acquired resistance
ensues. Early studies identiﬁed differential expression levels of
microphthalmia-associated transcription factor (MITF) in melanoma associated with distinct characteristic states and transcriptomic signatures5. The proliferative state was associated with
high levels of MITF, whereas the invasive state exhibited low
MITF but high expression of the epithelial-to-mesenchymal
transcription factor, ZEB1, and TGFβ signaling genes6. Differential expression of MITF, SRY (sex-determining region Y)-box
10 (SOX10), and BRN2/POU3F2 transcription factors, or p75
NGFR, deﬁne the invasive and proliferative states and provide
further subclassiﬁcation2,7–13. Despite this knowledge, the factors
required for phenotypic switching in melanoma remain poorly
deﬁned.
SOX10 is highly expressed during early NC development and
maintained in the migratory phase but is repressed as NC cells
differentiate. SOX10 expression is used as a marker for melanoma
and its role is intriguing. High SOX10 expression positively regulates melanoma cell proliferation, tumor growth, and
invasion14,15. In addition, SOX10 has been linked to response to
targeted therapies. A SOX10-deﬁcient, slow-cycling state has been
implicated in acquired resistance of BRAF-mutant melanoma to
BRAFi through upregulation of TGFβ1-EGFR signaling16. In
other studies, elevated MITF expression and an MITF-low/AXLhigh state have both been associated with BRAFi resistance17,18.
Stable acquired resistance may arise from an innate or adaptive
drug-tolerant state. Recent single-cell sequencing studies have
characterized proliferative/melanocytic, undifferentiated/invasive,
and neural crest-like drug-tolerant states, highlighting a nonmutational phenotypic adaptation2,9,11,12,19. Here, we show that
SOX10 is heterogeneously expressed in melanomas independently of treatment status. SOX10 loss is sufﬁcient to induce an
invasive slow-cycling state and tolerance to BRAFi and/or MEKi,
which together likely form the basis for acquired resistance.
Importantly, we identify a vulnerability of SOX10-deﬁcient melanoma cells based on the up-regulation of cellular inhibitors of
apoptosis-2 (cIAP2). Together, our ﬁndings provide a strategy to
target SOX10-deﬁcient subpopulations and reduce drug-tolerant
populations in melanoma.
Results
SOX10 expression is heterogeneous in melanoma. To identify
mediators of phenotype switching, we assessed SOX10 expression
at the single-cell level in melanoma patient samples using a
publicly available single-cell RNA-sequencing (scRNA-seq)
dataset20 and observed both inter and intratumoral heterogeneity
(Fig. 1a, b). Thirteen of the 14 tumors analyzed were BRAF
inhibitor treatment-naïve. In addition, seven tumors were
immune checkpoint inhibitor (ICi) treatment-naïve (TN) and
seven were resistant to immune checkpoint inhibitors (ICR). Of
2

note, ICi-resistant patient tumors Mel110 and Mel106 were
homogeneously negative for SOX10 expression (Fig. 1a, b). In the
other 12 melanomas, SOX10-expressing and SOX10-deﬁcient
cells co-existed within the same tumor lesion. Evidence of
intratumoral heterogeneity was supported further at the protein
level by IHC analysis of melanomas showing clusters of tumor
cells with either low or high expression of SOX10 (Fig. 1c). To
further validate SOX10 heterogeneity in melanoma, we analyzed a
tumor microarray (TMA) obtained from 62 melanoma patient
samples21 (Fig. 1d). Twenty-eight samples (45%) were treatmentnaïve, 8 samples (13%) were treated with targeted therapy,
18 samples (29%) with ICi, and 7 samples (11%) with targeted
therapy and ICi. One of the tumor samples lacked treatment
information. Four samples were completely negative for SOX10,
while all the other tumor samples presented high intertumoral
and intratumoral-heterogeneity, corroborating our observations
from the scRNA-seq dataset20. SOX10 immunoﬂuorescence
analysis in A375 (BRAF V600E), MeWo (wild-type for BRAF and
NRAS), and 1205Lu (BRAF V600E) melanoma cell lines showed a
similar level of heterogeneity and conﬁrmed the co-presence of
SOX10-low and -high expressing cells in basal culture conditions
(Fig. 1e-g). Of note, we observed fewer SOX10-deﬁcient cells in
MeWo compared to the A375 and 1205Lu cell lines (data not
shown). Together, these data show that SOX10 is heterogeneously
expressed in melanoma and SOX10-low populations are present
in treatment-naïve samples.
SOX10 loss causes transcriptomic changes associated with an
invasive phenotype. Given the presence of SOX10-negative cells
in pretreatment melanoma, we sought to characterize this subpopulation. We used CRISPR/Cas9 and multiple guides to
knock out SOX10 in MeWo and A375 cells and generated multiple clones with loss of SOX10 expression for each cell line
(Fig. 2a). RNA-seq analysis and Gene Set Enrichment Analysis
(GSEA) were performed to characterize the SOX10-regulated
transcriptome and evaluate signiﬁcant pathway changes following
SOX10 knockout (Fig. 2b, c and Supplementary Fig. 1A, B). In
SOX10 knockout cells, we observed an enrichment in pathways
associated with the tumor microenvironment (epithelialmesenchymal transition, TGFβ signaling, extracellular structure
organization, apical junction, hypoxia, and angiogenesis) and
metabolism (glycolysis pathway), as well as enrichment of the p53
pathway and TNFA signaling via NFκB (Fig. 2b, c and Supplementary Fig. 1A, B). Additionally, we observed reductions in
MYC and E2F targets (Supplementary Fig. 1A). We further
corroborated the involvement of SOX10 in regulating these
pathways using two publicly available datasets11,16 containing
SOX10 knockdown transcriptome data from A375 cells and 6
different patient-derived melanoma cell lines (MM001, MM011,
MM031, MM057, MM074, MM087) (Supplementary Fig. 1C–E).
To determine the role of SOX10 in the transition between
phenotypic states, we compared CRISPR knockout SOX10 cells
with parental cell lines using the proliferative and invasive
signatures identiﬁed by Verfaillie, et al.6. SOX10 knockout cell
lines showed enrichment of invasive signature genes and a
reduction in proliferative signature genes (Fig. 2d and Supplementary Fig. 1F, G). Similar results were observed when the same
analysis was performed in datasets from SOX10 knockdown
melanoma cell lines11,16 (Supplementary Fig. 1H). These data
show that SOX10 loss is sufﬁcient to lead to transcriptional
alterations associated with phenotype switching to a low
proliferative/high invasive state.
SOX10 depletion induces an invasive-like state. To further
characterize the proteomic alterations associated with differential
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Fig. 1 Melanoma patient samples show heterogeneous SOX10 expression. a tSNE plot of scRNA-seq cells colored by SOX10 expression level from JerbyArnon, et al. b As in a except cells colored by treatment. c Melanoma patient samples from Thomas Jefferson Hospital stained for SOX10. Scale bars,
200 μm. d TMA samples stained for SOX10. In each sample, the percentage of cancer cells expressing none, low, medium, or high levels of SOX10 was
quantiﬁed by a pathologist (Dr. Xu). Samples were sorted based on their H-score (low to high). e Immunoﬂuorescence images of A375, cells stained for
SOX10 (green), ﬁlamentous actin (red), and DAPI (blue). The experiment was performed independently twice, and representative images are shown. Scale
bar, 100 μm. f As in e except MeWo cells were used. g As in e except 1205Lu cells were used.

expression of SOX10, we analyzed SOX10 knockout cells by
western blotting. We ﬁrst conﬁrmed that, as previously suggested,
SOX10 regulates the expression of ErbB322 and PDGFRβ16.
MeWo SOX10 knockout cells displayed increased protein levels
of the invasive markers ﬁbronectin (FN1), ZEB1, WNT5, N-

cadherin, and tyrosine-phosphorylated focal adhesion kinase
(FAK) (Fig. 3a). In addition, we detected reduced levels of the
proliferative markers MITF, phospho-RB1, and cyclin D3, as well
as upregulation in the cyclin-dependent kinase inhibitor, p21Cip1
(Fig. 3a). To address the concern of inter-clonal heterogeneity, we
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Fig. 2 SOX10 regulates the transcription of genes involved in invasion, proliferation, and cell metabolism pathways. a MeWo and A375 SOX10
knockout cell lines were generated as described in Materials and Methods. The same number of parental and SOX10 knockout cells were seeded in six-well
plates for each cell line. Cells were lysed and lysates western blotted as indicated. The experiment was repeated independently three times with similar
results. b A heatmap showing GSEA normalized enrichment scores (NES) for the hallmark gene sets collection for MeWo and A375 SOX10 knockout cells
(guide #2 and #4) compared to parental cells. NES values are displayed for enriched gene sets, using a Benjamini-Hochberg False Discovery Rate (BHFDR)
cutoff of 0.05. MeWo gRNA#2 includes combined data collected from clones # 2.1, # 2.2, and # 2.8. For all other samples (MeWo gRNA #4, and A375
gRNA#2 and gRNA#4), shown is the mean from three independent replicates generated for each clone. c Enrichment plots of EMT, Hypoxia, MYC targets1 and MYC targets-2 comparing MeWo and A375 SOX10 knockout cells (guide #2 and #4) with parental cells. d Enrichment plots of proliferative and
invasive gene signature (Verfaille, et al.) for MeWo and A375 CRISPR SOX10 knockout (guide #2 and #4) vs parental cells. BHFDR < 0.001.

additionally co-mixed the four MeWo SOX10 knockout clones at
equal ratios to generate a SOX10 knockout pool. Consistently, we
observed similar changes in invasive and proliferative markers in
the MeWo SOX10 knockout pool and A375 SOX10 knockout
cells when compared to MeWo and A375 parental cells, respectively (Supplementary Fig. 2A, B).
4

Based on the upregulation of ﬁbronectin and increased tyrosine
phosphorylation of FAK, we further explored alterations in
extracellular matrix (ECM) production and remodeling. FN1 is
often secreted by the mesenchymal compartment whereas
collagen IV is commonly produced by tumor cells. Consistent
with the mesenchymal phenotype observed in SOX10-deﬁcient
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Fig. 3 SOX10 regulates the expression of genes associated with a slow-cycling and more invasive phenotype. a The same number of MeWo parental
and MeWo CRISPR SOX10 knockout (clone # 2.1; 2.2; 2.8; 4.11) cells were seeded in six-well plates for each cell line. Cells were lysed and lysates western
blotted as indicated. The experiment was repeated independently two times with similar results. b MeWo parental, MeWo #2.1, and MeWo #4.11 cells
were plated on coverslips coated with 0.2% gelatin. The next day, cells were treated with ascorbic acid (50 µg/ml) for 6 days. Treatment was renewed
every 48 h. At the end of the experiment, cells were permeabilized, ﬁxed, and stained for FN1 and collagen IV. The experiment was performed
independently twice, and representative images are shown. Scale bars, 50 μm. c Scratch-wound assay comparing MeWo CRISPR SOX10 knockout (clones
# 2.1; 2.2; 2.8; 4.11) cells to parental cells. Shown is the mean ± SD from three independent experiments. p-values were calculated using a two-sided t-test
and p-values for signiﬁcant comparisons are shown. d Spheroid in 3D collagen comparing MeWo CRISPR SOX10 knockout (clones # 2.1; 2.2; 2.8; 4.11) cell
lines to parental cells. Shown is the mean ± SD from three independent experiments. Scale bar, 25 μm. p-values were calculated using a two-sided onesample t-test of the null hypothesis and p-values for each comparison are shown.
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cells, extracellular deposition of FN1 appeared increasingly
organized in ﬁbrillar structures in SOX10 knockout MeWo cells
compared to the parental cells (Fig. 3b and Supplementary
Fig. 2C, D). Conversely, no change was observed in collagen IV
(Fig. 3b). These results suggest that SOX10 alters ECM
production. Since cancer cell-derived ECM is associated with
invasion23, we performed migration and invasion assays. In 2D
IncuCyte scratch-wound healing assays, SOX10 knockout cells
traveled signiﬁcantly farther than controls (Fig. 3c and Supplementary Fig. 2E). In 3D collagen spheroid assays, SOX10
knockouts displayed decreased core area but increased outgrowth
(Fig. 3d and Supplementary Fig. 2F). These data suggest that
SOX10 loss induces an invasive state associated with increased
production of ECM components organized in ﬁbrillar structures.
SOX10 loss is sufﬁcient to induce a quiescent/dormant-like
phenotype in vivo. Since cancer cell-derived ECM is associated
with invasion23 and dormancy24, to determine if the enhanced
invasive properties of SOX10 knockout cells were associated with
a slow-cycling phenotype, we examined the growth of luciferaseexpressing MeWo intradermal xenografts. Parental MeWo cells
generated tumors that typically reached a palpable size within two
weeks (Fig. 4a). In contrast, SOX10 knockout MeWo cells failed
to form palpable tumors, but luciferase imaging showed the
presence of residual cancer cells at the sites of injection (Fig. 4b
and Supplementary Fig. 3A). These residual cells remained
detectable at three months post-injection (Fig. 4c). IHC staining
of residual tumors (at day 35) conﬁrmed the lack of SOX10
expression (Supplementary Fig. 3B) and showed signiﬁcantly
reduced Ki67 and increased p21Cip1 levels compared to control
tumors, indicating reduced proliferation (Fig. 4d and Supplementary Fig. 3C). Next, to evaluate whether SOX10 knockout
causes alterations in the ECM in vivo, we used second-harmonic
generation of polarized light microscopy to visualize polymerized/
ﬁbrous collagen bundles at the residual tumor areas. Consistent
with the in vitro data (Fig. 3b), SOX10 knockout tumors showed
enrichment in ﬁbrous ECM signatures (Fig. 4e, f and Supplementary Fig. 3D). Overall, our in vivo studies suggest that SOX10
knockout cells display a quiescent/dormant-like phenotype
associated with increased ﬁbrous ECM protein deposition/
organization.
SOX10 is downregulated in melanomas resistant to MAPK
targeting agents. Loss of SOX10 has been previously linked to
acquired resistance to BRAFi in BRAF-mutant melanoma16.
These ﬁndings prompted us to characterize SOX10 deﬁciency in
the context of targeted therapy tolerance. First, we compared the
effect of MAPK targeting agents in parental versus SOX10
knockout cells in both BRAF wild-type and BRAF-mutant models. Parental MeWo and A375 cells were highly sensitive to either
MEKi or BRAFi + MEKi treatments, respectively (Fig. 5a and
Supplementary Fig. 4A-C). By contrast, SOX10 knockout cells
were signiﬁcantly less sensitive to MEKi and BRAFi + MEKi
treatments (Fig. 5a and Supplementary Fig. 4A-C). In the A375
parental cells, we detected reduced SOX10 expression in the
surviving population following 14 days of BRAFi + MEKi
treatment (Supplementary Fig. 4D). To investigate whether
SOX10-deﬁcient cells preferentially survive MEKi, we co-mixed
optically bar-coded mCherry-SOX10-proﬁcient and GFP-SOX10deﬁcient cells at a 2:1 ratio. We used this ratio since SOX10negative/low cells often appear to be a subclonal population in
melanoma patient samples. In the absence of treatment, SOX10proﬁcient cells grew out, whereas chronic exposure to MEKi
selected for SOX10-deﬁcient cells (Fig. 5b and Supplementary
Fig. 4E).
6

One possibility is that acquired resistance to targeted therapy
arises, at least in part, from cells in a drug-tolerant state. We
analyzed the expression of SOX10 in cell lines previously
generated in vitro and in vivo that are tolerant/resistant to
BRAFi or BRAFi + MEKi1,25. All tolerant/resistant cell lines
analyzed showed dramatically reduced levels of SOX10 expression compared to their parental counterparts (Fig. 5c, d and
Supplementary Fig. 4F). The expression of SOX10 was not
affected by the presence/absence of the inhibitors, suggesting that
the loss of SOX10 is mediated by neither acute drug
administration26–28 nor by addiction to the inhibitors that can
develop following acquired resistance29,30. Of note, SOX10 loss
was more evident in cell lines generated in vivo compared to
in vitro. Consistent with SOX10 knockout cells (Fig. 2c, d and
Supplementary Fig. 1A–H), GSEA analysis of tolerant/resistant
lines, namely, A375 CRTs (CRT34 and CRT35, combination
BRAFi/MEKi-resistant tumors) and 1205Lu PBRTs (PBRT15 and
PBRT16 BRAFi-resistant tumors), showed enrichment in
epithelial-mesenchymal transition (EMT), TGFβ signaling, apical
junction, hypoxia, glycolysis, and TNFα signaling via NFκB, as
well as a reduction in MYC and E2F targets (Supplementary
Fig. 4G–I). Furthermore, the resistant/tolerant cells (CRTs and
PBRTs) displayed an enriched invasive gene signature and
reduced proliferative gene signature6 compared to their respective
parental cells (A375 and 1205Lu) (Supplementary Fig. 4J, K).
When comparing the transcriptomic proﬁles of SOX10-deﬁcient
cells that arose following BRAFi + MEKi treatment in vivo
(CRT35 and CRT34) to SOX10 CRISPR knockout cells generated
in vitro, we observed a similar transcriptomic pathway enrichment and gene regulation (Fig. 5e, f). These data suggest that
many of the pathway alterations observed in the CRT lines may
be driven by the repression of SOX10.
Consistent with the SOX10 knockout phenotype, CRT34 and
CRT35 showed an increase in ECM protein deposition (Fig. 5g, in
the presence of BRAFi/MEKi, and Supplementary Fig. 4L, at basal
condition) and increased outgrowth in 3D collagen in comparison to A375 parental cells (Supplementary Fig. 4M). Next, we
queried published RNA-seq datasets from matching patient
samples before and after acquiring resistance to MAPK targeting
agents16. Consistent with the cell line-derived RNA-seq data
(Fig. 2c, d and Supplementary Fig. 1A–H and 4G–I), GSEA
analysis showed that resistant tumors lacking SOX10 or with a
SOX10-deﬁcient transcriptomic proﬁle displayed enrichment in
genes involved in EMT, hypoxia, TGFβ signaling, apical junction,
angiogenesis, TNFA signaling via NFκB, glycolysis, and extracellular structure organization (Fig. 5h and Supplementary
Fig. 4N). Resistant tumors also displayed an enriched invasive
gene signature and a reduced proliferative gene signature6
compared to pretreatment biopsies (Fig. 5i). In the transcriptomic
proﬁle of CRT lines, many pathways associated with proliferation
(E2F targets and MYC targets) were downregulated in the
presence of BRAFi + MEKi, consistent with drug-tolerant (versus
fully resistant) properties (Supplementary Fig. 4O). Consistent
with reduced G1/S progression, RB1 phosphorylation was
decreased and p27Kip1 expression was increased following BRAFi
+ MEKi treatment of CRT lines (Supplementary Fig. 4P). These
data indicate that a drug-tolerant SOX10-negative population
often arises following the treatment of melanoma with BRAFi
and/or MEKi, and that this might be the population of cells that
seeds tumor recurrence.
SOX10-negative cells are sensitive to cIAP inhibitors. Our data
indicate that SOX10 knockout cells display a targeted therapytolerant state associated with invasive properties. Next, we sought
to identify drugs that are selectively lethal for SOX10 knockout
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cells with the intent of targeting drug-tolerant persister cells. To
this end, we screened a total of 1820 compounds using the anticancer library compound panel in parental and SOX10 knockout
MeWo cells. Notably, all ﬁve cIAP1/2-XIAP inhibitors included
in the screen (LCL161, birinapant, GDC0152, AZD5582, and
BV6) effectively induced cell death in SOX10 knockout cells with
little-to-no effect on parental cells (Fig. 6a). Embelin, a XIAP
selective inhibitor, did not induce death in any of the cell lines
analyzed (Fig. 6a). Thus, cIAP1 and/or cIAP2 may be relevant
targets for inducing cell death in SOX10 knockout cells.
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To validate our results, we focused on the cIAP1/2 inhibitor,
birinapant, which is currently in clinical trials for head and neck
squamous cell carcinoma (NCT03803774). We conﬁrmed
reduced expression of cIAP1/2 and XIAP following birinapant
treatment by western blot analysis to show on-target effects
(Supplementary Fig. 5A). In IncuCyte growth assays, birinapant
reduced cell growth in SOX10 knockout cells compared to
parental cells in a statistically signiﬁcant manner, either at all
doses analyzed for MeWo #2.1 or at higher doses (50 and
100 nM) for MeWo #4.11 (Fig. 6b and Supplementary Fig. 5B).
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Fig. 4 Loss of SOX10 induces a dormant/quiescent phenotype in vivo. a Average tumor volume ±SEM for MeWo parental and SOX10 knockout clones
#2.1 and #4.11. Number of mice per cohort as indicated in the ﬁgure. b Average Luciferase signal (Avg Radiance [p/s/cm²/sr]) ±SEM for MeWo parental
and SOX10 knockout clones #2.1 and #4.11. Number of mice per cohort as indicated in the ﬁgure. c Luciferase signal in MeWo #2.1 (2 mice) and #4.11 (2
mice) 90 days after injection. Mice injected with parental MeWo cells did not survive 90 days; hence, their exclusion from the 90 days imaging. d IHC
comparing p21Cip1 and Ki67 expression in MeWo parental versus SOX10 knockout (clones #2.1 and #4.11) tumors collected at the end of the experiment
(day 35). Shown is the mean ± SD from three independent tumors generated either from parental or SOX10 knockout MeWo cells. Scale bar, 200 μm.
p-values were calculate using two-sided t-test. e Representative images showing second-harmonic generation signatures from three independent tumors
from MeWo parental or SOX10 knockout xenografts. Images shown correspond to reconstituted monochromatic images pseudocolored according to
“intensity heat-maps” of total second-harmonic generation signal. Warmer tones indicate higher second-harmonic generation signals (color tone bar is
provided). Scale bars, 50 μm. f Quantitative analysis of polymerized collagen signatures from images in e. Three independent tumors generated either from
parental or SOX10 knockout MeWo cells were analyzed. In total, 12 images from parental and 7 images from SOX10 knockout cells tumors were assessed.
Values presented are normalized to MeWo parental xenograft. Data are expressed as mean ± SD. p = 0.025. p-values were calculated using the Wilcoxon
two-sample test.

Birinapant elicited a similar, albeit less strong, effect in SOX10
knockout A375 cells (Supplementary Fig. 5C). A comparable
trend was observed in parental and SOX10 knockout MeWo cells
treated with GDC0152 and LCL161 (Supplementary Fig. 5D, E).
To identify the mechanisms involved in the differential
response of SOX10-deﬁcient versus -proﬁcient cells to cIAP
inhibitors, we analyzed the expression of IAP proteins. Strong
upregulation of cIAP2 expression was detected in SOX10
knockout cells, while cIAP1 and XIAP levels were relatively
unchanged (Fig. 6c). High cIAP2 levels were also observed in
SOX10-deﬁcient NRAS mutant melanoma cells, WM1361 and
WM1366 (Supplementary Fig. 5F), which are known to be less
sensitive to MEKi-induced cell death compared to other SOX10proﬁcient NRAS mutant cell lines31. To evaluate the clinical
relevance of a SOX10-cIAP2 negative correlation, we analyzed a
single-cell RNA-seq publicly available dataset obtained from
patient-derived melanoma cell lines11. SOX10 expression was
signiﬁcantly associated with decreased BIRC3/cIAP2 RNA-seq
counts (Fig. 6d and Supplementary Fig. 5G). Furthermore, a
signiﬁcant negative correlation was conﬁrmed by analyzing the
cutaneous melanoma mRNA expression TCGA dataset (Supplementary Fig. 5H).
Previous studies have suggested that low SOX10 expression
characterizes the “undifferentiated” cell state10, which has been
associated with resistance to targeted therapy2 and ICi32. Thus,
we analyzed the expression of BIRC3 across different cell states
expressing various levels of SOX10. RNA-seq data derived from
human10 and mouse32 cell lines conﬁrmed that BIRC3 mRNA
levels are upregulated in the “undifferentiated”, SOX10 low/
negative state (Supplementary Fig. 5I, J). However, a similar
upregulation was observed in the Neural Crest Stem Cell
(NCSC)-like state, which expresses SOX10 (Supplementary Fig. 5I,
J). Since the NCSC-like state retains a low level of MITF, this
transcription factor may play a role, but further studies are
necessary. Importantly, both “undifferentiated” and “NCSC-like”
states have been associated with resistance to ICi and MAPKi,
mirroring the cross-resistance observed in patients treated with
immune or targeted therapy.
Increased expression of cIAP2, and to a lesser extent cIAP1,
was observed in SOX10-deﬁcient A375-derived CRT lines
compared to parental A375 cells (Fig. 6e). Similarly, higher levels
of cIAP2 were observed in 1205Lu-derived SOX10-deﬁcient
PBRT16 cells compared to parental 1205Lu cells (Supplementary
Fig. 5K). SOX10-deﬁcient CRT35 and CRT34 cells showed
selective sensitivity to birinapant, starting at 0.5 and 0.1 μM,
respectively, compared to parental A375 cells (Fig. 6f and
Supplementary Fig. 5L, M). Interestingly, BRAFi + MEKi elicited
a degree of protection to CRT cells in vitro against the effects of
birinapant (Fig. 6f and Supplementary Fig. 5N, quantiﬁed in
Fig. 5O).
8

Given the ability of SOX10-deﬁcient cells to increase ﬁbrous
ECM protein deposition/organization (Figs. 3b, 4e, and 5g), we
next queried whether birinapant treatment inhibits these
alterations in ECM production and remodeling. A reduction of
ECM protein deposition was observed in MeWo SOX10 knockout cells and SOX10-deﬁcient A375 CRT35 cells treated with
birinapant; however, it will be important to separate these effects
from the ability of birinapant to induce cell death in SOX10deﬁcient cells (Supplementary Fig. 5P, Q).
Since birinapant has been utilized clinically, we tested its effects
in combination with BRAFi+MEKi in A375 xenograft models.
Co-treatment with birinapant signiﬁcantly delayed the onset of
BRAFi+MEKi resistance and improved mice survival (Fig. 6g,h
and Supplementary Fig. 5R, S). The triple combination (BRAFi +
MEKi+birinapant) versus BRAFi+MEKi caused more complete
and durable responses and cleared tumors did not reoccur
following drug removal. IHC analysis of SOX10 expression
showed that BRAFi/MEKi/birinapant-treated tumors expressed a
signiﬁcantly higher level of SOX10 compared to the control
tumors. (Supplementary Fig. 5T). These data support the notion
that targeting the SOX10-negative subpopulation improves the
durable efﬁcacy of BRAFi+MEKi.
Discussion
Given intratumor heterogeneity in cutaneous melanoma, an
important issue is to characterize the states associated with
phenotypic switching. Understanding the mechanistic switches to
drug-tolerant subpopulations and selectively targeting them is
likely to improve treatment for Stage III and IV melanoma. We
focused on SOX10, a transcription factor that is readily expressed
in melanoma lesions33,34 and often used as a diagnostic marker35.
Our ﬁndings demonstrate that SOX10 is heterogeneously
expressed in treatment-naïve melanoma samples. Additionally,
we found that SOX10 loss characterizes an invasive but dormant/
quiescent-like phenotype that represents a phenotypic switch
from the proliferative state of SOX10-expressing cells. The
quiescent-like state is associated with tolerance to MAPK targeting agents but renders cells sensitive to cIAP1/2 inhibitors
(Fig. 7). The cIAP1/2 inhibitor, birinapant, improves the durable
efﬁcacy of BRAFi+MEKi. Our studies underscore the importance
of targeting SOX10-deﬁcient subpopulations to prevent invasion
and drug tolerance.
We show that the expression of SOX10 can direct melanoma
cells towards a proliferative state and that its loss leads to invasive
characteristics. Conversely, a previous study suggested that a
reduction in SOX10 expression down-regulates invasiveness15. It
is known that depletion of SOX10 reduces cell proliferation and
induces senescence36,37, and that Sox10 over-expression in zebraﬁsh promotes melanoma formation14. Our study shows that
SOX10-deﬁcient melanoma cells are slow-cycling, which is an
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effect associated with reduced expression of MITF and cyclin D3
as well as enhanced p21Cip1. Other studies suggest that SOX10
may mediate effects on melanoma growth and survival via regulation of the long non-coding RNA, SAMMSON, and mitochondrial homeostasis38, via control of SOX939 and/or through
regulation of the small GTPase RAB740. How these mechanisms,
in combination with MITF loss, contribute to the slow-cycling
phenotype awaits further examination. Furthermore, the invasive

Proliferative

Collagen IV

FN1

Invasive

i

phenotype of SOX10-deﬁcient cells was associated with upregulated
ZEB1, FN1, and FAK phosphorylation. ZEB1 is an EMT transcription factor known to induce ECM remodeling41. FN1 is often
secreted by the mesenchymal compartment whereas collagen IV is
commonly produced by tumor cells. FAK signals downstream of
integrins which are activated by FN1, collagen IV, and other ECM
proteins, all of which have been previously associated with resistance to the BRAFi, vemurafenib42. FAK inhibitors are being tested
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Fig. 5 SOX10 loss induces tolerance to MAPK targeting agents. a Cells were treated with 50 or 100 nM trametinib. Treatment was renewed three times
per week. Shown is the mean ± SD from three independent experiments. p-values were calculated using two-sided model-based t-test tests and adjusted
for multiple testing using the Hochberg method and represent statistical analysis comparing growth inhibition of MeWo parental vs MeWo #2.1 and
MeWo #4.11 from day 0 to day 10. p-values are shown. b mCherry-MeWo and GFP-MeWo SOX10 knockout #2.1 or #4.11 cells were co-mixed at the ratio
of 2:1. Cells were co-cultured for 90 days in the presence or absence of 50 nM trametinib. Co-cultures were collected and analyzed by FACS for mCherry
and GFP positivity. c Cells were treated with 1 µM PLX4720 plus 35 nM PD325901 for 24 h. Cells were lysed and western blotted as indicated. The
experiment was repeated independently three times with similar results. d Cells were treated with BRAFi (500 nM PLX8394). Cells were lysed and
western blotted as indicated. The experiment was repeated independently three times with similar results. e Venn diagrams showing the commonality of
enriched gene sets (BHFDR < 0.05) from the Hallmark gene set collection (n = 50) for comparisons between A375 gSOX10 or CRTs in the presence of
BRAFi+MEKi and parental control groups. f A scatter plot showing differential gene expression for gSOX10 and CRT groups over parental A375. Wald’s
test statistic was averaged across the gSOX10 #2 and gSOX10 #4, and the CRT34 and CRT35, conditions. Red dots and gene names indicate the top 10
most signiﬁcantly up and downregulated genes for the CRT and gSOX10 groups, and genes that are common between CRT and gSOX10are labeled in red.
g Cells were treated with 1 µM PLX4720 + 35 nM PD0325901. Treatment was renewed every 48 h. Cells were stained for FN1 and collagen IV. The
experiment was performed independently twice, and representative images are shown. Scale bars, 50 μm. h Enrichment plot of EMT (BHFDR < 0.001)
comparing patient samples before and after MAPK targeting treatment from the Sun. et al. dataset. i Proliferative/invasive signature (Verfaille, et al.) for
patients post vs pretreatment, controlled for patient (Sun, et al.).

clinically and may be useful for blocking the spread/growth of
slow-cycling invasive cells. Changes in ECM ﬁbrillogenesis, ﬁrst
noted by the Keely group43, have been reported in a plethora
of solid tumors44,45 and were shown to be clinically relevant in
melanoma46,47.
Slow-cycling melanoma cells have been linked to drug
tolerance48. We show that SOX10 deﬁciency is sufﬁcient to cause
MAPK targeted therapy tolerance and that BRAFi and/or MEKi
treatment preferentially selects for SOX10-deﬁcient cells. SOX10
loss is associated with melanomas that have acquired resistance to
BRAFi16. Furthermore, SOX10-negative clones have been identiﬁed in the minimal residual disease of BRAF-mutant PDX
models following BRAFi and MEKi and in ‘on-treatment’ patient
samples2. The selective outgrowth of SOX10-deﬁcient cells on
MEKi suggests that acquired resistance to MAPK targeted therapy may arise from pre-existing SOX10-deﬁcient cells. We show
that SOX10-deﬁcient/low cells are present to varying levels in
treatment-naïve tumors. Whether the loss of SOX10 is driven by
genomic alterations or reversible epigenetic events, as previously
suggested6,49, needs further elucidation. While our study focused
on signaling pathway-targeted inhibitors, the role of SOX10 in
response to immune-based therapies also needs evaluation. We
note that both of the SOX10-negative melanomas from the singlecell sequencing dataset were ICi-resistant20, and preclinical studies suggest that low levels of SOX10 are associated with a lack of
response to ICi32. Additionally, analysis of publicly available
datasets10,32 indicates that “NCSC-like” and “undifferentiated”
states, which have both been associated with resistance to targeted
and immune therapies, express high levels of BIRC3 mRNA. A
future direction will be to investigate the role of BIRC3 in tolerance/resistance to targeted therapies and immunotherapy, and
whether cIAP2i can prevent or delay the onset of resistance for
both therapies. Data from the literature suggest that cIAP2 can be
regulated post-translationally50,51, thus, it will be important to
assess cIAP2 protein levels across cell states moving forward.
The properties of SOX10-deﬁcient cells led us to identify novel
therapeutic strategies to target this subpopulation with the goal of
enhancing targeted therapy regimens. Broad genomic and pharmaceutical screens have identiﬁed synthetic lethal drug combinations and drug-gene connections that lead to the death of
distinct cellular populations. A pharmacological inhibitor screen
identiﬁed a class of cIAP1/2 inhibitors as selectively targeting
SOX10-deﬁcient cells, an effect likely due to a dramatic upregulation of cIAP2 proteins. The cIAPs, a family of structurally
related proteins, including XIAP (X-linked IAP), cIAP1, cIAP2,
and survivin, are known to inhibit apoptosis by blocking the
activation of effector caspases. IAPs inhibitors (also known as
10

SMAC mimetics) cause the degradation of cIAP1 and 252. Previous studies have shown that birinapant inhibits the growth of
many melanoma cell lines if combined with TNF-α treatment21.
In preclinical models, birinapant synergizes with TRAF2 inactivation to induce tumor volume reduction and extend survival in
mice, likely impacting T cell functionality53. Addition of anti-PD1
to this combination induced superior tumor control and
improved overall survival in mouse models.
Multiple monovalent, as well as bivalent, cIAP1/2 inhibitors
have entered clinical cancer trials. In general, these compounds
are well tolerated and have a reasonable safety proﬁle; however,
they have shown limited clinical activity as single agents54. Previous studies showed synergistic effects of birinapant in combination with BRAFi in BRAF V600E colorectal cancer cells55.
Consistently, our data suggest that adding cIAP1/2 inhibitor to
the regimen of BRAFi and MEKi will delay the onset of acquired
resistance.
An interesting aspect of this strategy is that, at least in vitro,
BRAFi+MEKi elicited a protective effect on SOX10-deﬁcient cells
treated with birinapant. Previous studies have suggested that
BRAFi-resistant cells develop drug addiction rendering them
sensitive to drug withdrawal29; however, results from clinical trial
data with BRAFi+MEKi indicate that continuous treatment
regimens are more effective56. Further studies are needed to
identify optimal scheduling of birinapant with BRAFi+MEKi
combinations to maximize tumor regression durability and
minimize potential toxicity. In addition, investigating cIAP1/2
inhibitor effects on the tumor immune microenvironment may
provide insights into how these agents might potentially interact
with ICi. Together these ﬁndings raise several potential strategies
for the incorporation cIAP1/2 inhibitors into treatment regimens
for cutaneous melanoma.
Methods
Cell culture. MeWo cells (kindly donated by Dr. Barbara Bedogni, when at Case
Western Reserve, Cleveland, OH in 2014), A375 parental cells (purchased from
ATCC in 2005), and vehicle-treated xenograft derived A375 cells (A375 CTL) were
cultured in DMEM with 10% FBS. A375 BRAFi+MEKi combination tolerant/
resistant cells (CRT33, CRT34, and CRT35, previously labeled as CRT13, CRT14,
and CRT151) were cultured in the presence of PLX4720 (1 μM) and PD325901
(35 nM). 1205Lu and 1205LuTR GAL4-ELK1 reporter cells were modiﬁed from the
parental line (generated by Dr. Meenhard Herlyn, The Wistar Institute, Philadelphia, PA in 2005). 1205Lu, paradox breaker resistant tumor (PBRT) #15 and #16
cells25, and SKMEL28 cells (purchased from ATCC in 2002) were cultured in
MCDB153 (Sigma) with 2% FBS, 20% Leibowitz L-15 medium, and 5 μg/ml
insulin. 1205Lu-PBRT #15 and #16 and SKMEL28-PBRT cells were cultured in 0.5
μmol/L PLX8394. BRAF and NRAS mutation status in cell lines was validated by
Sanger sequencing. Cells were assayed for mycoplasma contamination every two
months with MycoScope Kit (Genlantis). Short-tandem repeat analysis was completed for parental and CRISPR SOX10 knockout MeWo cells and the respective
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SOX10 knockout, and tolerant/resistant A375 cells (October 2020), for 1205Lu
(January 2021) and for 1205LuTR GAL4-ELK1 reporter and PBRT cells (February
2017). All cell lines matched known proﬁles. Cells were cultured at 37 °C with 5%
CO2 in a humidiﬁed chamber.
CRISPR. To generate CRISPR SOX10 knockout cells, MeWo and A375 cells were
co-transfected with Edit-R Cas9 plasmid harboring puromycin-resistance marker
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(Horizon Discovery, U-005100-120), two different crRNAs for SOX10
(guide#02, Horizon Discovery CM-017192-02-0002, target sequence GATGGTCAGAGTAGTCAAAC, and guide#04, Horizon Discovery CM-017192-04-0002,
target sequence GTCCAACTCAGCCACATCAA), and tracrRNA using DharmaFECT Duo (Horizon Discovery). After 48 h, puromycin was added to the medium,
and cells were selected for growth. Individual clones were expanded and tested for
SOX10 knockout by western blotting. To generate the MeWo SOX10 knockout
pool, clones #2.1, # 2.2, # 2.8, and #4.11 were co-mixed at equal ratios.
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Fig. 6 Synthetic lethality of IAP inhibitors towards SOX10-deﬁcient population. a Synthetic lethality of IAP1/2-XIAP inhibitors toward the SOX10deﬁcient population expressed as inhibition of cell viability. b The same number of cells were seeded for each cell line. Cells were treated with increasing
concentrations of birinapant. Treatment was renewed every 48 h. Shown is the mean ± SD from three independent experiments. p-values were calculated
using two-sided model-based t-test tests and adjusted for multiple testing using the Hochberg method and represent statistical analysis comparing
birinapant-induced growth inhibition in MeWo parental vs MeWo #2.1 and MeWo #4.11. p-values are shown. c Cell lysates were western blotted, as
indicated. The experiment was repeated independently three times with similar results. d scRNA-seq cell line data for SOX10 and cIAP2/BIRC3. p < 0.001
for zero-inﬂation model and p = 0.002 for mean model. e Cells were treated with PLX4720 (1 µM) + PD0325901 (35 nM) for 24 h, lysed and western
blotted. The experiment was repeated independently three times with similar results. f The same number of cells were seeded for each cell line. Cells were
treated with increasing concentrations of birinapant. Treatment was renewed every 48 h. Shown is the mean ± SD from three independent experiments.
p-values were calculated and adjusted as in b. and represent statistical analysis comparing birinapant-induced growth inhibition in A375 parental vs CRT35
or CRT34 cells. p-values are shown. g A375 xenograft tumor growth, day 0 corresponding to the ﬁrst day of treatment. Mice were treated 200 PPM
PLX4720 plus 7 PPM PLX2695 and/or injected with 100 μL (for female mice) or 150 μL (for male mice) birinapant solution (3 mg/ml). AIN-76A diet was
used as vehicle. Number of mice per cohort as indicated. Statistical signiﬁcance was calculated as the time to tumor regrowth (tumor volume > 100 mm3)
and corresponding median survival times were estimated using the Kaplan–Meier method. The two-sided log-rank test was used to compare the time to
regrowth between treatment groups. p-value is shown. h Mouse survival curve for the in vivo experiment shown in g. p-values were calculated using the
two-sided log-rank tests and were adjusted for multiple testing to control for the False Discovery Rate (FDR) using the method of Benjamini and Hochberg.
p-values are shown.

ECM remodeling
Invasive phenotype
Slow cycling cell

FN1

SOX10

cIAP2
p21Cip1

+

SOX10 proficient cell

+
+

-

SOX10 deficient cell

+

MAPKi

+
-

-

+

Second mutation
-

+
Tolerant persister cells
MRD
MAPKi
+ Birinapant

-

Acquired resistance

Second mutation
-

Fig. 7 Schematic showing the effects of SOX10 loss in melanoma. SOX10 loss leads to an invasive but dormant-like/quiescent phenotype associated with
ECM remodeling and tolerance to MAPK targeting agents. SOX10-deﬁcient cells show upregulation of cIAP2 that is associated with sensitivity to cIAP1/2
inhibitors.
Generation of luciferase and ﬂuorescent-labeled cells. For luciferase labeling,
MeWo parental and CRISPR SOX10 knockout cells were transduced with pLentipuro TO/V5-GW ﬁreﬂy luciferase plasmid and selected for using puromycin. For
mCherry labeling, MeWo cells were transduced with pLV-mCherry (Addgene
#36084), and highly expressing cells were sorted. A similar approach was followed
for GFP labeling of MeWo CRISPR knockout SOX10 #2.1 and #4.11 cells, except
that the pLV-eGFP (Addgene #36083) plasmid was used.
Inhibitors. Dabrafenib (BRAF inhibitor), PD0325901 (MEK inhibitor), trametinib
(MEK inhibitor), and birinapant were purchased from Selleck Chemicals. PLX4720
(BRAF inhibitor), PLX2695 (MEK inhibitor), and PLX8394 (BRAF inhibitor) were
provided by Dr. Gideon Bollag (Plexxikon Inc., Berkeley CA).
Single-cell sequencing analysis. Single-cell RNA-Seq data for seven treatmentnaïve and seven immune checkpoint inhibitor-resistant melanoma patient tumors
originated from Jerby-Arnon, et al.20. These included tumors with at least
50 malignant cells. The Single Cell Portal (https://portals.broadinstitute.org/
single_cell/study/melanoma-immunotherapy-resistance) was used to generate
tSNE plots of malignant cells. A loom ﬁle containing scRNA-seq data of 10
cutaneous melanoma cell lines from Wouters et al.11 was obtained from http://
scope.aertslab.org/#/Wouters_Human_Melanoma. SCopeLoomR (v0.10.2 https://
github.com/aertslab/SCopeLoomR) was used to load preprocessed cell line data
12

into R (v4.0.2 https://www.R-project.org/). Pseudo-counts per million data were
calculated from raw counts using the edgeR package (v 3.30.3)57. Normalized
counts and tSNE coordinates were used to plot gene expression levels of each
cell. Scatter plots were generated using the ggplot2 package (v 3.3.2 https://
ggplot2.tidyverse.org).
Bulk RNA-seq sample prep, data acquisition, and analysis. For MeWo CRISPR
SOX10 and parental cell line samples, total RNA (100 ng) was used to prepare
libraries using TruSeq Stranded Total RNA kit (Illumina, CA) by following the
manufacturer’s protocol. The ﬁnal libraries (at the concentration of 4 nM) were
sequenced on NextSeq 500 using 75 bp paired-end chemistry. For A375 CRISPR
SOX10, parental, and CRT samples, 200 ng aliquot of each sample was transferred
into library preparation, which uses an automated variant of the Illumina TruSeq™
Stranded mRNA Sample Preparation Kit. The ﬁnal libraries were sequenced on
Illumina NovaSeq 6000 using 101 bp paired-end with an eight-base index barcode
read. Raw FASTQ sequencing reads for three patients with pretreatment and post
MAPK pathway inhibitor resistance tumor samples were obtained from the
Sequence Read Archive under the accession number SRP029434 using the SRA
toolkit (v 2.10.4)58.
For each dataset above, raw FASTQ sequencing reads were mapped against the
reference genome of Homo sapiens (Ensembl Version GRCh38.p12). Further
information was utilized from the gene transfer format annotation by GENCODE
(v28 or v30) using RSEM (v1.2.28)59. Total read counts and normalized
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Transcripts Per Million (TPM) were obtained using RSEM’s calculate-expression
function. Batch effects and sample heterogeneity were tested for using iSeqQC (v1.0
https://github.com/gkumar09/iSeqQC)60. Differential gene expression between
paired-sample patient tumors or guide RNA and control samples were tested for
using the DESeq2 package (v1.28.1)61. Genes were considered differentially
expressed (DE) if they had an adjusted p ≤ 0.05 and an absolute fold change ≥2.
Gene Set Enrichment Analysis (GSEA v3.0 or v4.0.1)62, was performed to identify
signiﬁcantly altered pathways. The MSigDB Hallmark gene set collection (v6.2 or
v7.0)63, GO Biological Process gene sets64, and invasive and proliferative signatures
from Verfaillie et al.6 were used for analyses. The DESeq2 test statistic was used as a
ranking metric to perform GSEA in pre-ranked mode, with genes having zero base
mean or “NA” test statistic values ﬁltered out to avoid providing numerous
duplicate values to GSEA. GSEA pre-ranked analysis was performed using the
“weighted” enrichment statistic. The number of permutations was set to 1,000, and
FDR q-values equaling zero are reported as less than 0.001. Venn diagrams,
heatmaps and scatter plots were generated using the VennDiagram (v1.6.20 https://
CRAN.R-project.org/package=VennDiagram), pheatmap (v1.0.12 https://
CRAN.R-project.org/package=pheatmap) and ggplot2 (v3.3.2 https://
ggplot2.tidyverse.org/) packages in R (v3.5.1 or v4.0.2 https://www.R-project.org/).
The RNA-seq data generated for this publication can be found under NCBI
BioProject numbers PRJNA701949, PRJNA748713, and PRJNA748714.
Immunoﬂuorescence. A375, MeWo, and 1205Lu cells were grown on coverslips
overnight, washed with PBS, and ﬁxed with 4% formaldehyde for 10 min. Fixed
coverslips were washed three times with PBS and incubated with 2% BSA/0.2%
Triton X-100 in PBS for 30 min at room temperature to permeabilize cells and
block nonspeciﬁc staining. Coverslips were then incubated with primary SOX10
antibody (Abcam [SP267], ab227680, 1:200) diluted in 2% BSA/0.2% Triton X-100
in PBS overnight at 4 °C. After washing three times in PBS, coverslips were
incubated for 1 h at room temperature with Alexa Fluor 488 (Invitrogen, A-11034,
1:1000) conjugated secondary antibody, Phalloidin-TRITC (Sigma, P1951, 1:500)
to visualize the cytoplasm, and DAPI (Abcam, ab228549, 1:1000) to visualize
nuclei. Coverslips were mounted and imaged using a 40X objective lens on a Nikon
A1R Microscope with NIS-Elements AR software.
Immunohistochemistry. Deidentiﬁed patient samples were collected from Thomas
Jefferson Hospital under an IRB-approved protocol (#10D.341) which includes
written informed consent and was in accordance with recognized ethical guidelines.
Sections from formalin-ﬁxed and parafﬁn-embedded (FFPE) tumors were stained
with SOX10 antibody (Abcam [SP267], ab227680, 1:200). Selected areas of SOX10deﬁcient cells were evaluated by two different pathologists: Dr. Hookim (Thomas
Jefferson University) and Dr. Xu (University of Pennsylvania) and identiﬁed as
cancer cells. Tissue microarrays (TMA) were generated at the University of
Pennsylvania and information about the tumor samples was obtained from Krepler, et al.21. The TMA contained 13 Stage III melanoma samples, 1 Stage III/IV
melanoma sample, and 38 Stage IV melanoma samples. Stage information was not
available for 6 of the samples. Tumors were stained with SOX10 antibody (Abcam
[SP267], ab227680, 1:200). Samples were derived from 64 melanoma patients and
each patient sample was present on the TMA in duplicate. However, two patient
samples (WM3901 and WM4115) were excluded from the analysis because the
tissue was no longer suitable for IHC. In each sample, the percentage of cancer cells
was classiﬁed, based on SOX10 expression, as negative (intensity = 0), low
(intensity = 1), medium (intensity = 2) and high (intensity = 3) by Dr. Xu. The H
score for each tumor was calculated according to the formula: H-score = intensity
1 x area + intensity 2 x area + intensity 3 x area. For each patient the H-score was
calculated as the average of the sample duplicates. For nine of the tumors analyzed,
only one replicate was deemed suitable for analysis.
For xenograft staining, MeWo, MeWo CRISPR SOX10 #2.1, and MeWo
CRISPR SOX10 #4.11 tumors were harvested from mice at 35 days post-injection.
Tissues were processed for FFPE and stained with anti-Ki67 (Abcam, ab16667,
1:200), anti-p21Cip1 (Cell Signaling, #2947, 1:200), and anti-SOX10 (Abcam
[SP267], ab227680, 1:200) antibodies. The percentages of Ki67 and p21Cip1 positive
cells were evaluated by a pathologist (Dr. Xu). Additional information regarding
the IHC protocol is included in Supplementary Methods.
Anti-cancer library compound panel drug screen. Cell viability screening against
the MCE anti-cancer library (1820 compounds) was performed using CellTiterGlo® (Promega). Both control and SOX10 knockout cells were maintained in
complete media, trypsinized, and plated at 500 cells/well in 40 µL of complete
media the day before the experiment in white, clear bottom 384-well plates. 50 nL
of test compound was added to each well using the Janus MDT Nanohead (Perkin
Elmer). Each compound was screened at a ﬁnal concentration of either 10, 1,
and 0.1 µM. After a 72 h incubation at 37 °C + 5% CO2, 20 µL of CellTiterGlo
reagent was added to each well. After 15 minutes, luminescence was measured
using the Envision Multi-mode plate reader (PerkinElmer). The raw data were
normalized to % inhibition, where 0% is the RLU in the presence of DMSO only,
and 100% is the RLU in the presence of 1 µM bortezomib. Estimated IC50 values
for each compound were determined using nonlinear regression ﬁts on the data to
a one-site binding model in XlFit (IDBS). Because only 3 data points were used in
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this calculation, the top and bottom of the curve were ﬁxed to 100, and 0%,
respectively, with a constant slope value of 1.
ECM ﬁbers orientation. Tri-dimensional monochromatic z-plane stacked images
were two-dimensionally reconstituted to maximal projection images of FN1 and
collagen IV using FIJI software65 (ImageJ 1.53f51, https://imagej.net/software/ﬁji/).
Aided by the same software, an initial screening evaluated the percentage of ﬁbers
area coverage (% FAC) per image. For this, a ﬁxed threshold based on grayscale
pixel intensity was used to discriminate ECM ﬁber structures from disperse
cytosolic signal within the cells. An arbitrary cutoff value of 20% FAC was set and
only images above this value (see Supplementary Fig. 2C) were processed for ﬁber
orientation analysis. Using FIJI’s plugin OrientationJ (Biomedical Image Group,
http://bigwww.epﬂ.ch/demo/orientation/), as described before66,67, a comprehensive orientation analysis68 was conducted using similar plugin settings for all the
images evaluated. In brief, the mode angle calculated for each image was set to 0˚
and the rest of angle readouts normalized accordingly, followed by the adjustment
of angle ﬂuctuations between a range of −90° to 90°. The percentage of ﬁbers
oriented within −15˚ and 15˚ from the mode angle was determined for each
normalized set, where greater percentages reﬂect higher levels of ﬁbers
organization.
Microscopy and analysis of second-harmonic generation (SHG) of polarized
light. Tissue specimens processed for FFPE were sliced (~4 µm), mounted on
microscopy slides, deparafﬁnized using xylene, rehydrated with progressive ethanol
to water dilutions, rinsed in PBS, and redehydrated in progressive ethanol concentrations. Specimens were clariﬁed in toluene before being mounted using
Cytoseal-60 (Thermo Fisher Scientiﬁc, Waltham, MA), and then cured overnight in
the dark prior to imaging. As described69, SHG imaging was conducted in a Leica
SP8 DIVE confocal/multiphoton microscope system (Leica Microsystems, Inc.,
Mannheim, Germany) equipped with a 25X HC FLUOTAR L 25x/0.95NA W
VISIR water-immersion objective. Samples were illuminated at 850 nm with an IR
laser Chameleon Vision II (Coherent Inc., Santa Clara, CA) and backward emission
settings were used to collect second-harmonic generation signals, via a nondescanned detector that was conﬁgured to register between 410 and 440 nm
wavelengths. Regions of interest were selected by a pathologist (Dr. Xu) who had
knowledge of the sample’s condition but was blinded to the expected result. Using
the automated Leica Application Suite X 3.5.5 software, each of these areas was
acquired by the collection of 2–4 regions, using identical settings and recorded as
monochromatic 16-bit TIFF images, via stacks containing an average of 5.5 images
(1 μm distance between each z-plane).
Image processing and digital analyses were conducted using FIJI software65. In
brief, raw z-image stacks were reconstituted as two-dimensional maximal
projections images. Signal to noise thresholds was set identical for all images and
positive-signal areas were used to calculate integrated second-harmonic generation
densities (e.g., SHG signal/SHG area). Data were normalized to the MeWo parental
second-harmonic generation integrated density mean value. Results represent
arbitrary units compared to control tissues.
Western blot analysis. Proteins were extracted with Laemmli sample buffer,
resolved by SDS-PAGE, and transferred to PVDF membranes. Immunoreactivity
was detected using HRP-conjugated secondary antibodies (CalBioTech, Spring
Valley, CA) and chemiluminescence HRP-recognizing substrates (ThermoScientiﬁc, Waltham, MA) on a VersaDoc Multi-Imager. Primary and secondary
antibodies used are listed in Supplementary Methods. Uncropped blots are supplied in the Source Data ﬁle.
Cell growth assay (IncuCyte). Cells were plated in single wells of six-well plates.
Cell growth was analyzed for percent plate coverage with IncuCyte Live Cell
Analysis System. Forty-nine pictures per well were acquired every 24 h.
Scratch-wound assay. Cells were plated in single wells of IncuCyte ImageLock96-well plates. The next day, cells were treated with mitomycin (1 μg/mL) for 2 h
before the monolayer was scratched using the IncuCyte WoundMaker tool. Cells
were washed with PBS and serum-free media (SFM) with 1% BSA was added to
each well. Wound healing was analyzed by wound width (μm) using the IncuCyte
Live Cell Analysis System. IncuCyte ScratchWound analysis software was used to
take two pictures every 12 h per well. Signiﬁcance was calculated by comparing
CRISPR SOX10 knockout cells to parental cells at either 24, 48, or 72 h.
ECM protein staining. MeWo parental and MeWo SOX10 knockout cells
(5 × 105), CRT cells (3 × 105), and A375 parental cells (1.25 × 105) were
plated on coverslips coated with 0.2% bovine gelatin and treated with ascorbic acid
(50 µg/ml) every 48 h for 6 days. Cells were processed as previously described68,70.
Brieﬂy, samples were washed with DPBS + and ﬁxed/permeabilized for 20 min
using 4% paraformaldehyde with 5% sucrose and 0.1% Triton X-100 added.
Samples were then washed twice with DPBS- with 0.05% Tween-20 and blocked
for 1 h at room temperature in Odyssey Blocking Buffer containing 1% donkey
serum. Samples were stained with FN1 (Sigma, #F3648, 1:200) and collagen IV
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(Abcam, ab86042, 1:75) antibodies diluted in Odyssey Blocking Buffer for 1 h at
room temperature. After three washes with DPBS- containing 0.05% Tween-20,
samples were incubated with secondary antibodies (AlexaFluor-488 Invitrogen
A-11034 1:1000 and AlexaFluor-594 Invitrogen A-11032 1:1000 or AlexaFluor-647
Invitrogen A-21236 1:1000) for 30 min at room temperature. Nuclei were stained
with DAPI (Abcam, ab228549, 1:1000). After washing three times in DPBS- with
0.05% Tween-20, coverslips were mounted and pictures were taken with A1R
Nikon confocal Ti-Eclipse inverted microscope (Nikon, Melville, NY) using NISElements software.
3D spheroid. 5000 cells/well were plated in a 96-well plate coated with 1.5% agarose
and were grown in suspension for ﬁve days to form spheroids. Spheroids were
harvested and implanted into 3D collagen as previously described31. Brieﬂy, spheroids
were collected from 96-well plates using a transfer pipette and allowed to settle for 1 h.
A 24-well plate was coated with a collagen mixture (rat tail Collagen Type I containing Reconstitution Buffer, Ham’s F-12 Nutrient Mix, and 5% FBS) and incubated
for 20 min at 37 °C. Spheroids were resuspended in a collagen mixture, plated on the
coated 24-well plates, allowed to set for 20 min at 37 °C, and covered with a normal
culture medium. After 4–7 days, spheroids were stained with Calcein AM (Invitrogen
C1430) diluted in PBS for 1 h before bright-ﬁeld images were taken with a C2 Nikon
confocal Ti-Eclipse inverted microscope (Nikon) using NIS-Elements.
Flow cytometry. GFP or mCherry expressing MeWo cells (3 × 105) were plated
and left to incubate overnight. The next day, cells were trypsinized, spun down,
washed twice with PBS, and resuspended in FACS Buffer (PBS with 1% FBS and
0.05% sodium azide). Cells were strained through a 70 μm cell strainer and
transferred to ﬂow tubes. Cells were run on a BD FACSCelesta (BD Biosciences;
Franklin Lakes, NJ) and FACS data were analyzed using Flowjo software (v10.6.1).
FSC-A/SSC-A plots were used to gate out cell debris. Then, the subsequent
population was gated on FSC-A/FSC-H to remove doublets. The resulting population was assessed for GFP and mCherry expression.
In vivo studies. Animal experiments were performed at a Thomas Jefferson
University facility that is accredited by the Association for the Assessment and
Accreditation of Laboratory Animal Care. The Institutional Animal Care and Use
Committee at Thomas Jefferson University approved these studies (Protocol #:
01052). All animals were provided with food and water ad libitum, and housed in
cages (with a maximum of 5 mice/cage) in a temperature and humidity-controlled
environment. Animals were maintained in housing conditions that allow for
normal species behavior to minimize the development of abnormal behaviors and
have access to humane and veterinary care. Three million MeWo parental or
CRISPR SOX10 knockout cells (#2.1 and #4.11) were injected intradermally into
the backs of NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. Digital caliper
measurements of the tumors were taken twice per week, and tumor volumes were
calculated using the formula: volume = (length × width2) × 0.52. In vivo bioluminescence detection was conducted using the Caliper IVIS Lumina-XR System
(Caliper Life Sciences), and data acquisition was conducted using LivingImage
Version 4.0 software. For ﬁreﬂy luciferase, mice were imaged after 10 min of
intraperitoneal injection of d-luciferin (150 mg/kg).
For the A375 in vivo xenograft study, one million cells were injected
intradermally into the backs of athymic mice (NU/J, homozygous, Jackson,
6–8 weeks, 20–25 g). When tumors were palpable, mice were randomly sorted into
four cohorts. Mice were treated with BRAFi + MEKi (PLX4720 200
PPM + PLX2695 7 PPM) and/or injected intraperitoneally, twice per week, with
100 μL (for female mice) or 150 μL (for male mice) birinapant solution (formulated
at 3 mg/ml in 5% DMSO and 15% captisol, CyDex Pharmaceuticals, aqueous
solution). AIN-76A diet was used as vehicle. To prevent weight loss, after 14 days
of treatment, the mouse diet was supplemented with ClearH2O DietGel® Recovery
and bacon softies (Bio-Serv) one day per week. At the end of the experiment the
mice that did not present tumors (n = 2 for BRAFi+MEKi and n = 4 for BRAFi
+MEKi+birinapant cohorts) were removed from treatment and observed for an
additional 30 days. None of the mice developed tumors following treatment
removal. Digital caliper measurements of the tumors were taken twice per week,
and tumor volumes were calculated using the formula: volume = (length × width2)
× 0.52. Mouse weights were monitored once a week.
Statistical analysis. For scratch-wound assays, statistical analysis was performed
using Student’s two-sample t-tests, assuming unequal variance. For the 3D spheroid
assay, the area of outgrowth and the core were compared between each MeWo
SOX10 knockout and parental cells using the two-sided one-sample t-test of the null
hypothesis. For analysis of second-harmonic generation (SHG) of polarized light
(ECM ﬁbers orientation), Wilcoxon two-sample test was used for two-group
comparison. The Hodges-Lehmann estimate of location shift with the corresponding exact 95% conﬁdence interval was computed to estimate the difference in
integrated second-harmonic generation densities between MeWo and MeWo
SOX10 knockout. For the IncuCyte experiments comparing parental and SOX10deﬁcient cells (CRISPR knockouts and CRTs), statistical analysis was performed as
described: for each plate (replicate within treatment and dose) the log-transformed
net conﬂuency increase (lnNCI) at each day (D) (lnNCI(D)) from day 1 to the end
14

of the experiment was deﬁned as the difference between log-transformed conﬂuence
at day D and log-transformed conﬂuence at day 0. Log-transformed increases (for
day ≥ 1) were analyzed in a longitudinal linear mixed-effects model with the ﬁxed
effects of genotype, treatment (if multiple drugs), dose, time, and random effect of
the plate. Serial correlation between repeated over time measures in the same plate
were modeled using autoregressive covariance structure. The dependence on time
was modeled with a quadratic function. The ﬁtted models were used to estimate the
geometric mean proportion of growth inhibition (mPGI) for each treatment, nonzero treatment dose, and each genotype as the exponentiated mean difference
between mean lnNCI (treatment, dose=D, geno) and meanNCI (treatment,
dose=0, geno). The mPGI was compared between each clone and WT separately for
each treatment and non-zero dose D by computing the PGI ratio (exponentiated
mean difference in lnNCI). The p-values for the two-sided model-based t-test tests
were adjusted for multiple testing using the Hochberg method.
Statistical analysis for single-cell RNA-seq data was performed using separate
zero-inﬂated negative binomial (ZINB) regression models that model single-cell
RNA-seq counts of BIRC3 as dependent on SOX10 counts and the total RNA-seq
counts per cell as an exposure. The ZINB regression model includes a mean model
for the negative binomial mean of BIRC3 count as dependent on SOX10 counts,
and a zero-inﬂation probability model, which is essentially a logistic regression
predicting the odds of zero counts as dependent on SOX10 counts.
For A375 in vivo studies, statistical analysis was performed to evaluate if the
BRAFi+MEKi+birinapant triple combination signiﬁcantly delayed the onset of
resistance in comparison to BRAFi+MEKi combination. Statistical signiﬁcance was
calculated as the time to tumor regrow (tumor volume > 100) from day 0 and
corresponding median survival times were estimated using the Kaplan–Meier
method. The log-rank test was used to compare the time to regrow between
treatment groups. For the mouse survival curve the time to sacriﬁce (in days) and
corresponding median survival times were estimated using the Kaplan–Meier
method. The log-rank test was used to compare the time to sacriﬁce between
treatment groups (i.e., global comparison and comparison between control and
each of 3 Tx group). The corresponding 95% CIs were also reported. In addition,
six pairwise comparisons of the time to sacriﬁce were conducted with log-rank
tests. p-values from these pairwise comparisons were adjusted for multiple testing
to control the false discovery rate using the method of Benjamini and Hochberg.
All the analyses were performed with SAS 9.4 (SAS Institute Inc., Cary, NC).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The RNA-seq data generated from the MeWo gSOX10, A375 gSOX10 and CRT, and
1205Lu TR PBRT samples are available under NCBI BioProject numbers PRJNA701949,
PRJNA748713, and PRJNA748714, respectively. Human and mouse reference genomes
(GRCh38.p12 and GRCm38.p6) and gene and transcript annotation data (v28, v30, and
M25) were obtained from GENCODE (https://www.gencodegenes.org/). MSigDB Gene
Set Collections (Hallmark and GO Biological Process, v6.2 and v7.0) were obtained from
https://www.gsea-msigdb.org/. Invasive and proliferative signatures were obtained from
https://static-content.springer.com/esm/art%3A10.1038%2Fncomms7683/MediaObjects/
41467_2015_BFncomms7683_MOESM1477_ESM.xlsx. Single-cell RNA-Seq
data for malignant cells from 7 treatment-naïve and 7 immune checkpoint inhibitorresistant melanoma patient tumors were originated from Jerby-Arnon, et al. 201820.
Normalized expression data for a single gene are publicly available to view in tSNE space
using the Single Cell Portal (https://portals.broadinstitute.org/single_cell/study/
melanoma-immunotherapy-resistance). Cell annotation and normalized expression
data are freely available for bulk download from the Single Cell Portal (https://
singlecell.broadinstitute.org/single_cell/) after registering for an account using a Googlemanaged identity (https://singlecell.broadinstitute.org/single_cell/terms_of_service).
A.loom ﬁle containing scRNA-Seq data for 10 melanoma cultures was obtained from
http://scope.aertslab.org/#/Wouters_Human_Melanoma. Patient tumors pre and post
MAPK pathway inhibitor therapy, 6 SOX10 knockdown and 6 parental melanoma cell
lines, 53 human melanoma cell lines, and 4 mouse melanoma cell lines data are available
in the SRA database under accession numbers SRP029434, SRP215051, SRP074198, and
SRP247646, respectively. Human melanoma cell line annotation data were gathered from
https://ars.els-cdn.com/content/image/1-s2.0-S1535610818301223-mmc2.xlsx. The
reporting summary for this Article is available in the Supplementary Information ﬁle. All
the other data supporting this study are available within this Article, Supplementary
Information, Source Data ﬁle, or from the corresponding authors upon reasonable
requests. Source data are provided with this paper.

Code availability
Computational analyses were done using publicly available software and R packages or
SAS 9.4 (SAS Inc., Cary, NC)
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